angiotensin II receptor blocker (ARB), a beta-blocker, and a statin, is recommended by the American College of Cardiology/American Heart Association/European Society of Cardiology (ACC/AHA/ESC) to optimize patients' outcomes in ACS. [3] [4] [5] The prescribing of a quadruple EBM regimen, after an ACS event, has been demonstrated to reduce cardiovascular morbidity and mortality. [6] [7] [8] [9] Despite the obvious benefits of an EBM combination on morbidity and mortality from developed countries, [6] [7] [8] [9] corresponding data from the Arabian Gulf, which is associated with a high prevalence of ACS, 10 are scarce.
Gulf COAST (Gulf locals with acute coronary syndrome events) was a prospective, multicountry, multicenter registry of consecutive Gulf citizens hospitalized with the final diagnosis of ACS in 4 Arabian Gulf countries (Bahrain, Kuwait, Oman, and United Arab Emirates) over a period of 12 months from 2012 to 2013. 11 Hence, the aim of this study was to assess the prevalence and impact of concurrent EBM prescribing on all-cause mortality in ACS patients in the Arabian Gulf.
| ME THODS
Details of the methods of the Gulf COAST registry have been reported previously. 11 Briefly, Gulf COAST registry was a prospective, multicenter, multinational, longitudinal, cohort study of consecutive citizens, from the Gulf region of the Middle East, admitted from January 2012 to January 2013 to 29 hospitals with a diagnosis of ACS. The registry enrolled a total of 4055 patients who were 18 years of age or older with ACS diagnosed according to American
College of Cardiology (ACC) clinical data standards. 12 Apart from excluding noncitizens and those who were not willing/able to provide consent to be included in the study, there were no other exclusion criteria. This study was approved by the local institutional ethics committees of participating centers.
Data collected included patient demographics, previous history and risk factors, prior medication use, laboratory data, clinical presentation and management during hospital stay including medications, reperfusion therapy and procedures, and discharge medications. Follow-up was performed at 1, 6, and 12 months from the date of enrollment and was carried out by clinic visits or telephone interviews.
The primary outcomes of this study were mortality rates at 1-month, 6-months, and 12-months as well as the corresponding adjusted odds ratios associated with the EBM prescribing.
| Statistical analysis
For categorical variables, frequencies and percentages were reported. Differences among groups were analyzed using Pearson's χ 2 tests (or Fisher's exact tests for cells < 5). For continuous variables, mean and standard deviation were used to present the data while analyses were performed using Student's t test. The association between concurrent EBM prescribing and mortality was evaluated by multivariate logistic regression utilizing the simultaneous method and adjusting for GRACE risk score for in-hospital mortality, which has been validated in an Arabian Gulf ACS registry. 13 Apart from GRACE risk score variables (which is derived from age, heart rate, systolic blood pressure, serum creatinine, cardiac ar- 
| RE SULTS
The Gulf COAST registry consisted of 4055 patients. However, 374
patients were removed due to missing information on discharged medications, in-hospital death, or left against medical advice. The final analysis cohort consisted of 3681 patients with an overall mean age of 60 ± 13 years of which 66% (n = 2436) were males. At 1-year follow-up, 3.6% (n = 134) of the patients were lost to followup. Almost a quarter of the patients (n = 896; 24%) were current smokers, and 2.9% (n = 108) were alcohol consumers. Comorbid conditions were common in this cohort particularly hypertension (n = 2390; 65%), dyslipidemia (n = 2088; 57%), and diabetes mellitus (n = 1967; 53%). A total of 69% (n = 2542) of the patients were on the EBM combination of antiplatelet, ACE-I/ARB, B-blocker, and statin after discharge. Those prescribed EBM were more likely to be male (P = 0.001), diabetics (P < 0.001), have a history of hypertension (P = 0.033), present with lower creatinine (P < 0.001) and ST segment elevation myocardial infarction (STEMI) (P < 0.001) Table 1 . Table 2 shows prior to admission and postdischarge medication utilization stratified by EBM prescribing. Prior to admission, the EBM group was more likely to be on ACEIs (P < 0.001), beta blockers (P < 0.001), and statins (P = 0.010). As expected, at discharge, the EBM cohort was more likely to be associated with aspirin (P < 0.001), clopidogrel (P < 0.001), ACEIs (P < 0.001), ARBs (P < 0.001), beta blockers (P < 0.001), statins (P < 0.001), oral nitrates (P = 0.041) but less likely to be associated with the prescribing of calcium channel blockers (P < 0.001). Of note, 72% (n = 2634) of the patients were on both aspirin and clopidogrel concurrently at hospital discharge.
As shown in Table 3 , the overall cumulative all-cause 1-month, 6-months, and at 1-year mortalities were 1.3% (n = 46), 4.9%
(n = 178), and 8.0% (n = 291), respectively. The 2-way interactions between EBM and age (P = 0.824), EBM and GRACE risk score BMI was missing in 41 subjects, HR in 2 subjects, SBP in 707 subjects, DBP in 2 subjects, creatinine in 18 subjects, LVEF was missing in 1261 subjects, and GRACE in 20 subjects. Percentages might not add up to 100% due to rounding off.
TA
| D ISCUSS I ON
This prospective, multinational, multicenter study from the Middle East showed that, a significant proportion (69%) of ACS patients was on the concurrent EBM combination therapy at hospital discharge.
Furthermore, after multivariate adjustment, the EBM combination was associated with significantly lower cumulative all-cause mortality when compared to patients who were not on the EBM combination therapy.
There has been a considerable variation in the prescribing of guideline-recommended EBM cardiac medications in ACS patients as shown in Table 4 ranging from 29% in the Canadian ACS I reg- Adj. OR, adjusted odds ratio; CI, confidence interval; EBM, evidence-based medication combination (consisting of antiplatelet therapy, angiotensinconverting enzyme inhibitor or angiotensin II receptor blocker, b-blocker, and lipid-lowering agent concurrently); HL, Hosmer & Lemeshow P-value; ROC, area under the receiver operating curve (also known as c-statistic). Multivariate analyses were conducted using logistic regression models utilizing the simultaneous method. The covariates in the models included GRACE risk score (derived from age, heart rate, systolic blood pressure, serum creatinine, cardiac arrest at admission, ST segment deviation on EKG, abnormal cardiac enzymes and Killip class), gender, diabetes mellitus, prior stroke/transient ischemic attack, atrial fibrillation, country of origin and type of acute coronary syndrome.
Over the 1-y study period, there were a total of 3.6% (n = 134) of losses to follow-up.
significantly improved in the Arabian Gulf region from 49% in the Gulf RACE I 16 in 2007 to 69% in the current Gulf COAST registry of 2013, which might reflect improved adherence to guideline recommendations. 3, 4 Significant utilization of the concurrent EBM prescribing has also been reported in Europe 17 and in China. 18 These modest estimates of concurrent EBM prescribing suggest a significant gap between the evidence and practice. This has been attributable to patient characteristics, hospital type, and lack of familiarity with current treatment recommendations by physicians. [19] [20] [21] Each of the EBM combination drug group has been demonstrated to reduce morbidity and mortality among patients with ACS. [22] [23] [24] [25] [26] However, these findings were in the controlled set- The positive impact of the quadruple EBM combination on mortality in this study has also been replicated elsewhere. [6] [7] [8] [9] In the Canadian ACS I and II registries, the prescribing of the optimal medical therapy was also associated with significantly lower 1-year mortality (aOR, 0.54; 95% CI: 0.36-0.81; P = 0.003) compared to those given 0 or 1 drug at discharge. 7 In the University of Michigan Health System's ACS registry, the prescribing of the EBM combination was also strongly associated with a 2-year survival when compared to those that received ≤1 EBM (aOR, 0.25; 95% CI: 0.15-0.41). Fifth, a total of 3.6% of the patients were lost to follow-up at 1-year.
However, this number was relatively small, and importantly, there TA B L E 4 Demographic, clinical, and presentation characteristics between the Gulf COAST group remaining at the end of the year and the cohort that was lost to follow-up (LTF) (N = 3681)
were no significant differences in the demographic, clinical, and presentation characteristics between the Gulf COAST group remaining at the end of the study year and the cohort that was lost to follow-up at 1-year (Table 4) .
| CON CLUS IONS
To our knowledge, this is one of only a few studies worldwide to evaluate and report on the prevalence and impact on the prescribing of a quadruple EBM combination on 1-month, 6-months, and
12-months of all-cause mortality in ACS patients. Majority of the patients were on the quadruple EBM combination. Concurrent EBM prescribing was associated with significantly lower all-cause 1-month, 6-months, and 12-months mortality in Arabian Gulf ACS citizens in the Middle East. The relative benefits of EBMs were also consistent across age, GRACE risk score, and discharge diagnosis. 
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